Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Common Equity: 2017-2024

Historic Common Equity for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $155.6 million.

  • Aclaris Therapeutics' Common Equity fell 7.72% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 7.72%. This contributed to the annual value of $155.6 million for FY2024, which is 1.03% down from last year.
  • Aclaris Therapeutics' Common Equity amounted to $155.6 million in FY2024, which was down 1.03% from $157.2 million recorded in FY2023.
  • Aclaris Therapeutics' Common Equity's 5-year high stood at $197.6 million during FY2022, with a 5-year trough of $37.6 million in FY2020.
  • For the 3-year period, Aclaris Therapeutics' Common Equity averaged around $170.1 million, with its median value being $157.2 million (2023).
  • As far as peak fluctuations go, Aclaris Therapeutics' Common Equity plummeted by 46.15% in 2020, and later surged by 424.15% in 2021.
  • Over the past 5 years, Aclaris Therapeutics' Common Equity (Yearly) stood at $37.6 million in 2020, then skyrocketed by 424.15% to $197.3 million in 2021, then climbed by 0.14% to $197.6 million in 2022, then declined by 20.46% to $157.2 million in 2023, then fell by 1.03% to $155.6 million in 2024.